Deutsche Bank Sticks to Its Buy Rating for Vodafone (VOD)
In a report released yesterday, Robert Grindle from Deutsche Bank maintained a Buy rating on Vodafone (VOD – Research Report), with a price target of £1.30. The company's shares closed last Friday at p76.88.
Confident Investing Starts Here:
Grindle covers the Communication Services sector, focusing on stocks such as Vodafone, Deutsche Telekom, and BT Group plc. According to TipRanks, Grindle has an average return of 3.4% and a 57.32% success rate on recommended stocks.
In addition to Deutsche Bank , Vodafone also received a Buy from DZ BANK AG's Matthias Volkert in a report issued on May 20. However, on the same day, J.P. Morgan maintained a Sell rating on Vodafone (LSE: VOD).
The company has a one-year high of p79.50 and a one-year low of p62.40. Currently, Vodafone has an average volume of 101.5M.
Based on the recent corporate insider activity of 43 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of VOD in relation to earlier this year.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Forbes
an hour ago
- Forbes
Quietly Burning Out? What To Do When Your Leadership Starts Lacking
Post by Dr Katie Best, Visiting Fellow at the Department of Management at LSE, Head Tutor on MBA Essentials and Chief Examiner on Core Management Concepts. Dr Best is the author of upcoming book, The Ten Toughest Leadership Problems (and How to Solve Them) (August 2025), and Leadership Coach and Consultant at KatieBest Associates. Today's most committed leaders are often deeply helpful, hyper-responsible, and always ready to step ... More up. But that very strength can become a trap Most leaders don't realise they're burnt out—because they're still high-functioning. They're answering emails, running meetings, and hitting deadlines. But under the surface, their energy, creativity, and confidence are quietly eroding. I used to think burnout looked like someone who's at home, signed off work with stress. But I've realised more recently that burnout doesn't just live its life away from work, it lives its life at the office, sending one more email, making another tough decision, and keeping going, seemingly endlessly — surviving, but certainly not thriving. This might sound at odds with how we typically imagine burnout, but it's entirely in line with the go-to definition from the World Health Organization: a state of chronic workplace stress that hasn't been successfully managed, marked by exhaustion, cynicism, and reduced effectiveness. In my upcoming book The Ten Toughest Leadership Problems (and How to Solve Them), I talk about how overloaded leaders often try to fix burnout with better productivity tools — when the real solution lies in changing the way they lead. Whether that means delegating, narrowing focus, or letting go of unrealistic expectations, the shift has to be strategic, not reactive. Today's most committed leaders are often deeply helpful, hyper-responsible, and always ready to step up. But that very strength can become a trap—keeping them constantly on alert, always anticipating the next high-stakes decision or crisis, unable to switch off. The problem? When we're depleted, we often can't see it. We normalize the stress—tell ourselves this is just what leadership looks like. Or if we do notice we're struggling, we deny it. Surely a good night's sleep or a productivity hack will fix it? But when you're at this point, it's not just a time management issue. Rather, it's a role design issue, a personal standards issue, or others' expectations being unrealistic. And depending on which of those it is, you need a plan to help you fix it. When the workload inherent to the job is too great, it's time to look at what needs taking away. If you are doing work meant for two people, or in a job that assumes 60 hours a week from the outset, something needs to change. If the load is genuinely unmanageable, you should consider solutions such as redistributing tasks, hiring support, or renegotiating deliverables. Share the problem with others, such as HR, your seniors and peers, so that work can be started on what must be done. If you're setting your own standards too high, it's time to choose what you can afford to drop. I call this 'strategic failure'. By that, I mean that high-functioning leaders are clear on what they're willing to fail at or let slide in order to protect what matters most. Make peace with strategic failure with the unimportant things to protect success in the critical ones. Also: work isn't everything. People who reach the end of their lives and are asked their regrets don't typically (if ever) say, 'well, I just wish I'd worked harder. I didn't achieve inbox zero enough of the time.' When others expect too much, it's time to reset the narrative. That might mean clearer boundaries, more transparent capacity-setting, or simply letting others see that you're human—not a machine. The strongest leaders don't absorb every ask—they model sustainable performance for their teams. Resetting your leadership energy starts with recognising that you're not lazy, disorganised, or underperforming — you're overloaded. And the solution isn't to 'power through.' It's to make strategic choices about what gets your time, your energy, and your attention. The ultimate consequences of burnout can be serious – if a leader fails to spot a critical error, loses a key client, or makes a bad financial decision, burnout starts to have significant and far-reaching consequences. And this is without considering the serious health risks which burnout, left untreated, can bring. The strongest leaders aren't the ones who absorb it all. They're the ones who lead differently — who model focus, clarity, and enough space to think. Not just for themselves, but for the people who are watching. Follow Dr Katie Best on LinkedIn. Follow LSE's Department of Management on LinkedIn. Check out our website.
Yahoo
an hour ago
- Yahoo
Deutsche Bank trims U.S. growth outlook, sees Fed on hold until December
-- Deutsche Bank economists released today an updated economic outlook for the U.S. economy, taking into account key shifts in global growth expectations. The research firm indicates that U.S. economic growth is holding up better than initially feared, though a notable slowdown is still anticipated in the second half of the year. As a result, Deutsche Bank forecasts U.S. real GDP growth at 1.0% for 2025 and 2.0% for 2026 on a quarter-over-quarter basis, translating to 1.6% and 1.7% on an annual average basis, respectively. Core PCE inflation in the U.S. is projected to reach 3.5% this year. This forecast supports Deutsche Bank's expectation that the Federal Reserve will delay further interest rate cuts until December. The bank also suggests that U.S. economic exceptionalism is diminishing as twin deficits weigh on the economy, leading to a bearish outlook on the dollar and upward pressure on term premia. In contrast, the Euro Area's economic situation is stabilizing, with a 2025 growth forecast of 0.8%, aligning with November's projections. Inflation in the Euro Area is gradually easing, and fiscal stimulus, particularly in defense and industrial policy, is expected to support European economic "exceptionalism." Germany is anticipated to experience a stronger growth rebound starting in 2026. China's economic outlook has shown modest improvement, with a projected growth rate of 4.7% in 2025. The United Kingdom is experiencing growth alongside declining inflation, while Japan's momentum has softened. India remains resilient, with growth expected to be 6.5% for both this year and the next. Deutsche Bank forecasts United States 10-Year to reach 4.5% and Germany 10-Year to rise to 3.0% by the year's end, indicating a more significant movement for German yields. The report notes that the dollar's dominance is waning, with valuation and capital flow dynamics becoming more influential. Related articles Deutsche Bank trims U.S. growth outlook, sees Fed on hold until December EU yet to receive U.S. letter demanding best trade negotiation offers BofA sees strong Q1 growth keeping Bank of Canada on hold in June
Associated Press
2 hours ago
- Associated Press
Hemogenyx Pharmaceuticals PLC Announces Placing to Raise £451,250 and Director's Dealing
THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION AS STIPULATED UNDER THE UK VERSION OF THE MARKET ABUSE REGULATION NO 596/2014 WHICH IS PART OF ENGLISH LAW BY VIRTUE OF THE EUROPEAN (WITHDRAWAL) ACT 2018, AS AMENDED. ON PUBLICATION OF THIS ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THIS INFORMATION IS CONSIDERED TO BE IN THE PUBLIC DOMAIN. Hemogenyx Secures £451,250 to continue its Phase 1 Clinical Trials And Director's Dealing LONDON, UK / ACCESS Newswire / June 3, 2025 / Hemogenyx Pharmaceuticals plc (LSE:HEMO) ('Hemogenyx Pharmaceuticals' or the 'Company') is pleased to announce that it has raised gross proceeds of £451,250 (before expenses) via an allotment to Vladislav Sandler of 250,000 new ordinary shares of £0.01 each ('New Ordinary Shares') at an issue price of 180.5p (the 'Issue Price'). The net proceeds of this fundraise will be dedicated to the continuation of the Phase I clinical trials for the Company's Chimeric Antigen Receptor T-cell therapy ('HG-CT-1"), aimed at treating relapsed/refractory acute myeloid leukemia in adults ('R/R AML'). As shareholders will be aware, the first two patients have now been infused with HG-CT-1. Issuance of the New Ordinary Shares The Company is currently unable to issue and admit the New Issue Shares without either the publication of an FCA approved prospectus or relying upon an exemption to the requirement to issue a prospectus. Consequentially, this fundraise involves the acceptance by Vladislav Sandler, CEO and director of the Company to subscribe for the New Ordinary Shares at the Issue Price pursuant to the employee offer exemption under Article1(4)(i) and 1(5) (h) of the UK Prospectus Regulation. Following allotment of the New Ordinary Shares, Vladislav Sandler has agreed to direct their issue to an institution, who will immediately sell these New Ordinary Shares at the same Issue Price to a purchaser identified by it (the 'Purchaser'). Warrants Concurrent with the purchase of the New Ordinary Shares, the Purchaser will receive warrants from the Company on a one-for-one basis. These warrants will be exercisable for a period of 36 months at an exercise price of 270 pence ('Exercise Price'), subject to adjustment in certain circumstances as set out in the warrant instrument including a reset of the Exercise Price if the Company completes a share issuance (or other transaction granting rights to subscribe for equity securities) during the Exercise Period at a price lower than the Exercise Price. Total Voting Rights Application will be made for the 250,000 New Ordinary Shares, which will rank pari passu in all respects with the existing Ordinary Shares of the Company, to be admitted to the FCA official list and to trading on the equity shares (transition) category of the Official List maintained by the FCA and to trading on the main market for listed securities of the LSE, which is expected to occur on or around 8.00 a.m. on 13 June ('Admission'). Upon Admission, the total number of issued shares and the total number of voting rights in the Company will be 4,593,539. The above figure of 4,593,539 should be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the share capital of the Company under the Financial Conduct Authority's Disclosure Guidance and Transparency Rules. The Company will keep the market informed of future developments as trials proceed. Dr Vladislav Sandler, CEO & Co-Founder of Hemogenyx Pharmaceuticals, commented: 'We are pleased to have secured funding from a committed investor at a premium to the prevailing market price - an indication of their confidence in the long-term potential of Hemogenyx and our HG-CT-1 program. This support enables us to continue advancing our Phase I clinical trial without undue dilution and at a pivotal moment in the development of our therapy for relapsed/refractory AML.' Market Abuse Regulation (MAR) Disclosure Certain information contained in this announcement would have been inside information for the purposes of Article 7 of Regulation No 596/2014 (as it forms part of UK domestic law by virtue of the European Union (Withdrawal) Act 2018) until the release of this announcement. The person responsible for arranging for the release of this announcement on behalf of Hemogenyx Pharmaceuticals plc is Dr Vladislav Sandler, Chief Executive Officer & Co-Founder. Director's Dealing Notification Enquiries: About Hemogenyx Pharmaceuticals plc Hemogenyx Pharmaceuticals is a publicly traded company (LSE: HEMO) headquartered in London, with its US operating subsidiaries, Hemogenyx Pharmaceuticals LLC and Immugenyx LLC, located in New York City at its state-of-the-art research facility. The Company is a clinical stage biopharmaceutical group developing new medicines and treatments to treat blood and autoimmune diseases. Hemogenyx Pharmaceuticals is developing several distinct and complementary product candidates, as well as platform technologies that it uses as engines for novel product development. This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit SOURCE: Hemogenyx Pharmaceuticals PLC press release
